NICE Technology Appraisals in the NHS in England (Innovation Scorecard), To December 2022

The Innovation Scorecard reports on the use of medicines and medicine groupings in the NHS in England, which have been positively appraised by the National Institute for Health and Care Excellence (NICE).NHS Digital has produced and published the Innovation Scorecard as an Official Statistic since January 2013 on behalf of the Office for Life Sciences. It can be used by local NHS organisations to monitor progress in implementing NICE Technology Appraisal (TA) recommendations.The scorecard is produced using a range of administrative data sources prior to publication and no additional central data collection is involved.In 2021, the publication series switched to use the Secondary Care Medicines data that is supplied by Rx-Info and now published by the NHS BSA through their open data portal to provide a richer source of data down to hospital Trust level. This data is not directly comparable with the secondary care data used in previous publications due to variations in the coverage and completeness and changes in some of the prescribing measures used to present volume of use in this publication.The estimates report has now been replaced with a methodology statement as the figures for estimated expected uptake have been integrated into the national level groupings dashboard.

The Innovation Scorecard reports on the use of medicines and medicine groupings in the NHS in England, which have been positively appraised by the National Institute for Health and Care Excellence (NICE).NHS Digital has produced and published the Innovation Scorecard as an Official Statistic since January 2013 on behalf of the Office for Life Sciences. It can be used by local NHS organisations to monitor progress in implementing NICE Technology Appraisal (TA) recommendations.The scorecard is produced using a range of administrative data sources prior to publication and no additional central data collection is involved.In 2021, the publication series switched to use the Secondary Care Medicines data that is supplied by Rx-Info and now published by the NHS BSA through their open data portal to provide a richer source of data down to hospital Trust level. This data is not directly comparable with the secondary care data used in previous publications due to variations in the coverage and completeness and changes in some of the prescribing measures used to present volume of use in this publication.The estimates report has now been replaced with a methodology statement as the figures for estimated expected uptake have been integrated into the national level groupings dashboard.